Home
Solution
Impact
R&D
Science
Publications
STEP study
Xinnate’s Expanded Access Policy
About
Team and Board
News and Events
All News
All Events
All Press Releases
Contact
epidermolysis bullosa
Home
News
Xinnate Receives FDA Rare Pediatric Disease Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
epidermolysis bullosa
